Fangsheng Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 268 million yuan, a year-on-year increase of 17.6%Zhitong·Oct 23, 2025 at 07:45 AM603998-1.24%
Fangsheng Pharmaceutical: Clinical trial for Relugolix tablets approvedZhitong·Oct 15, 2025 at 03:48 AM603998-1.24%
Fangsheng Pharmaceutical plans to acquire the marketing authorization for "Compound Acetate Dexamethasone Cream."Zhitong·Oct 9, 2025 at 03:20 AM603998-1.24%
Fangsheng Pharmaceutical: The summary report of the Phase II clinical trial for Zhilong Tongluo tablets has been obtainedZhitong·Sep 23, 2025 at 04:43 AM603998-1.24%
Fangsheng Pharmaceutical: Clinical trial for gynecological hemostatic and analgesic granules approvedZhitong·Sep 4, 2025 at 03:29 AM603998-1.24%
Fangsheng Pharmaceutical: Net profit in the first half of 2025 increased by 23.67% year-on-yearZhitong·Aug 28, 2025 at 05:26 AM603998-1.24%
The industrial hemp sector has undergone significant adjustments, and GETM has hit the daily limit downZhitong·Aug 21, 2025 at 08:51 PM603998-1.24%600232-0.46%
Fangsheng Pharmaceutical's subsidiary has received the drug clinical trial approval notice for its traditional Chinese medicine innovation drug research and development projectZhitong·Aug 10, 2025 at 02:51 AM603998-1.24%
Fangsheng Pharmaceutical: Actual controller Zhang Qinghua has been released on bail pending trialZhitong·Aug 7, 2025 at 06:36 AM603998-1.24%
Fangsheng Pharmaceutical: Plans to transfer the ownership of the "Qiangli Pipa Lu" drug variety to Kangpu PharmaceuticalZhitong·Jul 22, 2025 at 04:04 AM603998-1.24%
Fangsheng Pharmaceutical: Subsidiary Xiangqin Jietuo Granules approved for clinical drug trialsZhitong·Jul 11, 2025 at 03:17 AM603998-1.24%
KaiYuan Securities: Maintains "Buy" rating on Fangsheng Pharmaceutical as blood-nourishing, wind-dispelling, and pain-relieving granules bring new growthZhitong·Jun 10, 2025 at 02:16 AM603998-1.24%
Fangsheng Pharmaceutical: The innovative traditional Chinese medicine for nourishing blood, dispelling wind, and relieving pain has obtained the "Drug Registration Certificate."Zhitong·Jun 9, 2025 at 06:46 AM603998-1.24%
One of the concerted actors of Fangsheng Pharmaceutical's controlling shareholder has cumulatively increased its holdings by 423,300 sharesZhitong·May 14, 2025 at 04:01 AM603998-1.24%
Fangsheng Pharmaceutical: Hunan Kexin plans to sell 51% of its subsidiary hospital Changsha KexinZhitong·Apr 7, 2025 at 06:15 AM603998-1.24%300143+1.11%
